Volume 129, Issue 2
Cover Figure: p19INK4d regulates terminal erythropoiesis through GATA1 protein. See the article by Han et al.
WASHINGTON, January 12, 2017 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.
Temporal quantitative phosphoproteomics of ADP stimulation reveals novel central nodes in platelet activation and inhibition
In a plenary e-Blood paper, Beck and colleagues present a phosphoproteomic analysis to characterize the profiles of ADP-stimulated platelets. They delineate a complex dataset that can be used to develop assays to monitor platelet activation and to identify novel pharmacologic modifiers of platelet function.
Sickle cell anemia in sub-Saharan Africa: advancing the clinical paradigm through partnerships and research
In a Blood Forum article, McGann et al discuss the crushing burden of sickle cell disease in sub-Saharan Africa and offer approaches to improve survival through newborn screening and early interventions.
FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII
Yoon and colleagues extend chimeric antigen receptor (CAR) T-cell technology and the immunosuppressive properties of regulatory T cells (Tregs) to the suppression of factor VIII (FVIII) inhibitors by the creation of a FVIII-specific CAR Treg that effectively suppresses murine splenocyte response to FVIII in vitro and in vivo.
Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post–allogeneic HCT
Abu Zaid and colleagues examined biomarkers in over 200 transplant patients and identified markers predictive for nonrelapse mortality, overall survival, and chronic graft-versus-host disease.
Sensing of the microbiota by NOD1 in mesenchymal stromal cells regulates murine hematopoiesis
Iwamura et al further elucidate the effect of the microbiota on hematopoiesis, demonstrating that it regulates hematopoietic stem and precursor cell number through inducing NOD1 in mesenchymal stem cells; this in turn increases cytokine production that stimulates stem and progenitor cell proliferation.
CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression
New directions of research discussed in this series of reviews aim at targeting B-cell Tarafdar and colleagues present studies that help explain why chronic myeloid leukemia (CML) can persist despite tyrosine kinase inhibitor therapy. They demonstrate that CML stem cells downregulate major histocompatibility complex class II expression through JAK-mediated signaling, supporting a potential for immunomodulatory therapy or JAK inhibitors to eradicate the disease at the level of the stem cell.
Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.
ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.
blood® is a registered trademark of the American Society of Hematology.